Suchergebnisse - "Itolizumab"

PubPharm (7)

1

Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab

enthalten in: Clinical & translational immunology | 2020

von Caballero, A. | Filgueira, L. | Betancourt, J. | +25

2

Clinical and experimental evidence for targeting CD6 in immune-based disorders

enthalten in: Autoimmunity reviews | 2018

von Consuegra-Fernández, M. | Lin, F. | Fox, D. | +1

3

The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients : results from a 6-month, open-label Phase I clinical trial

enthalten in: Clinical and experimental immunology | 2018

von Rodríguez, P. | Prada, D. | Moreno, E. | +15

4

Commentary : CD6 As a Potential Target for Treating Multiple Sclerosis

enthalten in: Frontiers in immunology | 2017

von Consuegra-Fernández, M. | Isamat, M. | Lozano, F.

CommentOn: Proc Natl Acad Sci U S A. 2017 Mar 7;114(10 ):2687-2692. - PMID 28209777

5

Itolizumab in combination with methotrexate modulates active rheumatoid arthritis : safety and efficacy from a phase 2, randomized, open-label, parallel-group, dose-ranging study

enthalten in: Clinical rheumatology | 2016

von Chopra, A. | Chandrashekara, S. | Iyer, R. | +10

6

Itolizumab - a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis

enthalten in: Clinical, cosmetic and investigational dermatology | 2015

von Menon, R. | David, B.

ErratumIn: Clin Cosmet Investig Dermatol. 2015;8:295. - PMID 26082656

7

Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab

enthalten in: mAbs | 2014

von Aira, L. | López-Requena, A. | Fuentes, D. | +7

1
[1]